|
John, I don't expect any real impact on stock price from Canada's approval, due to small size of this market relative to CEA-Scan's existing market. Interesting note in the news release about intraoperative use of CEA Scan to guide removal of potentially cancerous tissue at the margins of the surgical field. Company does admit, however, that this "off label" use of CEA-Scan still requires FDA approval. Of course, the very fact that they mentioned it in the article at all was to plant "a seed" in minds of surgeons that they could, at their own volition, choose to use CEA Scan in this "off-label" manner even w/o FDA approval. Frankly, this is not likely to happen. Surgeons who need an intraoperative product will use Neoprobe's RigScan, which is just about to receive FDA approval. The intraoperative use of RigsScan required development of reliable miniature scintillation counters, none of which would be available to surgeons wanting to try CEA-Scan in the intraoperative mode. So, in my opinion, not too much to get excited about in this news release. We need sales of CEA Scan and we need approval of LeukoScan before I see this stock price increasing much. Best Regards, Bill. |
